Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA-Associated Vasculitis
Conditions
ANCA-Associated Vasculitis
Trial Timeline
Mar 15, 2017 → Nov 1, 2019
NCT ID
NCT02994927About Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine
Avacopan + Prednisone + Cyclophosphamide + Rituximab + Azathioprine is a phase 3 stage product being developed by Amgen for ANCA-Associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02994927. Target conditions include ANCA-Associated Vasculitis.
What happened to similar drugs?
0 of 1 similar drugs in ANCA-Associated Vasculitis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02994927 | Phase 3 | Completed |
Competing Products
3 competing products in ANCA-Associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| rituximab + Placebo | Roche | Phase 3 | 40 |
| CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids | Amgen | Phase 2 | 35 |
| Abatacept (Orencia) | Bristol Myers Squibb | Phase 2 | 27 |